欢迎来到《四川大学学报(医学版)》

左乙拉西坦及辛伐他汀对癫痫持续状态大鼠脑保护作用的实验研究

Protective Effects of Levetiracetam and Simvastatin on Pilocarpine-induced Epilepsy in Rat Models

  • 摘要: 目的 探讨左乙拉西坦、辛伐他汀单用或联用对癫痫持续状态(SE)模型大鼠的早期神经保护作用及其相关机制。方法 利用氯化锂-匹鲁卡品制作SE大鼠模型,将造模成功的大鼠分为4组,采用不同的处理方式(生理盐水即模型组、左乙拉西坦、辛伐他汀、左乙拉西坦+辛伐他汀),同时设空白对照组,将各组大鼠处死后取脑组织,采用免疫组化尼氏染色检测大鼠海马区神经元细胞形态及数量;Western blot检测大鼠海马区calpain-1蛋白表达。结果 免疫组化尼氏染色结果显示:与空白对照组相比,模型组大鼠海马区神经元变性,存活神经元细胞减少甚至消失,正常结构消失,表明SE后24 h,大鼠海马区神经元受到了严重损伤;与模型组比较,辛伐他汀组大鼠海马区神经元减少甚至消失,排列疏松紊乱,但差异无统计学意义,表明辛伐他汀不能改变海马神经元损伤;与模型组比较,左乙拉西坦组及左乙拉西坦+辛伐他汀组大鼠海马区神经元排列尚紧密,基本保持有序,说明左乙拉西坦单用或联用辛伐他汀均能明显减少海马神经元死亡,改变海马神经元变性,差异有统计学意义(\P<0.05),但两种处理方式之间差异无统计学意义; Western blot结果显示,与空白对照组比较,模型组大鼠海马区calpain-1蛋白表达显著增高,说明calpain-1可能参与到SE神经系统损伤的病理生理机制中;与模型组比较,辛伐他汀、左乙拉西坦、辛伐他汀+左乙拉西坦组calpain-1蛋白表达降低,差异有统计学意义(\P<0.05),表明辛伐他汀、左乙拉西坦及两种药物联用均能通过降低calpain-1蛋白表达,一定程度地抑制神经兴奋毒性损伤通路。结论 左乙拉西坦可能通过抑制calpain-1发挥早期(SE后24 h)神经保护作用,然而左乙拉西坦联用辛伐他汀并未发挥更优的作用,辛伐他汀没有早期神经保护作用。

     

    Abstract: Objective To determine neuroprotective properties of levetiracetam and simvastatin using rats with pilocaroine-induced epilepsy. Methods Epileptic rat models were randomly divided into 4 groups, each being exposed to saline, simvastatin, levetiracetam, or levetiracetam+simvastatin. Brain tissues of the rats were examined. Nissl staining was used to determine pilocarpine-induced neuronal loss in CA1 and CA3 of hippocampus. Western blot was used to detect calpain-1 expression of hippocampus. Results Severe cell death was found 24 h after seizures, with a level significantly higher than the controls. Compared with the saline-treated cells, simvastatin did not decrease severe cell death (\P>0.05), but levetiracetam and levetiracetam+simvastatin decreased severe cell death 24 h after seizures (\P<0.05). No significant differences were found between those treated with levetiracetam and those with levetiracetam+simvastatin. Compared with controls, overexpressed calpain-1 was found in the rats 24 h after seizures, which indicates that calpain-1 may be involved in the pathophysiological mechanisms of epilepsy. Compared with those treated with pilocarpine+saline, simvastatin, levetiracetam and levetiracetam+simvastatin reduced the level of calpain-1 24 h after seizures (\P<0.05). Conclusion Levetiracetam, not simvastatin, possesses neuroprotective properties, through changing calpain-1 expression levels. But levetiracetam plus simvastatin treatment does not have advantages over the choice of monotherapy. Simvastain does not possess neuroprotective properties at the early stage of epilepsy.

     

/

返回文章
返回